CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 µM) and PD-L1 (IC50: 0.039 µM). This compound promotes early fungal apoptosis, diminishes intracellular concentrations of IL-2, NLRP3, and NF-kappaBp65 proteins, incites mitochondrial impairment and ROS accumulation, and culminates in fungal cell lysis and death [1].
